Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-IMPACT pancreatic cancer study
ACTRN12622000378729Phase 2Active, not recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Aug 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, oxaliplatin, irinotecan, folinic acid, fluorouracil and 1 more in pancreatic adenocarcinoma (PDAC), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Proportion of participants receiving at least 80% of planned doses of neoadjuvant therapy. Started Aug 2022; status: active, not recruiting.
02
Drugs
durvalumaboxaliplatinirinotecanfolinic acidfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12622000378729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000378729.